
Alnylam cuts 2026 sales forecast, stock plunges over 28% after weak Q2 results
Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower-than-expected growth in its TTR product after initial launch demand normalized. This announcement followed the company’s disappointing second quarte...

